NL-OMON33156已完成不适用
Ascending single dose study of the safety, tolerability, and pharmacokinetics of PRM-151 administered to healthy volunteers and patients with idiopathic pulmonary fibrosis (IPF) - FIH of PRM-151
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy subjects: healthy, age: 18-55 yrs; BMI:18-33 kg/m2;
- •IPF Patients: IPF diagnosis, FVC>45% corrected for age, DLCO 40-80%, age: 18-72, BMI:18-33 kg/m2;
排除标准
- •Healthy subjects: Active inflammation; acute or chronic disease; positive drug screen
- •IPF Patients: amyloidosis, connective tissue disorder, COPD, tuberculosis, cystic fibrosis, acute disease state, positive drug screen
研究者
相似试验
已完成
不适用
ASCENDING SINGLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACO-DYNAMICS OF SRA-444 ADMINISTERED ORALLY TO HEALTHY ADULT SUBJECTSneurological disorder10011305DementiaNL-OMON30387Wyeth64
已完成
1 期
Healthy Volunteer, Single Ascending Dose Study of TP-317Inflammatory bowel diseaseOral and Gastrointestinal - Inflammatory bowel diseaseACTRN12624000239561Thetis Pharmaceuticals LLC24
进行中（未招募）
不适用
Single dose study in adolescents with High cholesterolHeterozygous Familial HypercholesterolaemiaMedDRA version: 14.1Level: PTClassification code 10058108Term: DyslipidaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10057099Term: Heterozygous familial hypercholesterolaemiaSystem Organ Class: 100000004850EUCTR2012-001443-49-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.24
已完成
不适用
A single ascending dose study to assess the safety, tolerability and pharmacokinetics of RO5428029 in healthy male subjectsHCVHepatitis C Virus infectioninfection of the liver10047438NL-OMON34361Roche Nederland B.V.60
已完成
不适用
Single dose escalation study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 2413555 after oral dosing in healthy male participants in a randomized, single-blind, placebo-controlled, group-comparison desigHeart FailureNL-OMON54965Bayer AG90